Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

pembrolizumab 1281 Specimen Handling 927 Carboplatin 835 Magnetic Resonance Spectroscopy 834 Cyclophosphamide 809 Cisplatin 733 Nivolumab 683 Paclitaxel 638 Radiotherapy 614 Gemcitabine 582 Biopsy 558 Bevacizumab 482 Dexamethasone 446 fludarabine 411 Docetaxel 385 venetoclax 371 Oxaliplatin 368 Capecitabine 364 Fluorouracil 360 atezolizumab 346 durvalumab 340 Rituximab 334 Drug Therapy 332 Doxorubicin 319 Blood Specimen Collection 317 Radiosurgery 317 Standard of Care 311 Pemetrexed 307 Ipilimumab 306 Radiation 286

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Miransertib × 1 year × Clear all

NCT04316546 2026-06-03

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡